Related Experiment Video

Updated: Dec 25, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

11.0K

MiR-134, Mediated by IRF1, Suppresses Tumorigenesis and Progression by Targeting VEGFA and MYCN in Osteosarcoma

Zhuo Ma1, Kai Li1, Peng Chen1

  • 1China-Japan Union Hospital of Jilin University, Changchun City, Jilin Province, 130033, China.

Anti-Cancer Agents in Medicinal Chemistry
|April 3, 2020
PubMed
Abstract

Insights

MicroRNA-134 (miR-134) inhibits osteosarcoma progression by targeting VEGFA and MYCN. Interferon Regulatory Factor 1 (IRF1) activates miR-134, suppressing tumor growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma (OS) is a primary bone cancer with high mortality due to metastasis.
  • MicroRNAs (miRNAs) are crucial regulators of cancer metastasis.
  • Dysregulation of miRNAs in OS metastasis offers potential therapeutic targets.

Purpose of the Study:

  • To investigate the role of miR-134 in osteosarcoma metastasis.
  • To identify the molecular mechanisms underlying miR-134's function in OS.
  • To explore the upstream regulators of miR-134 expression.

Main Methods:

  • In vitro assays (viability, invasion, migration, apoptosis) in OS cell lines (MG63, Saos-2).
  • Luciferase-reporter assays to confirm miRNA targets.
  • Real-time PCR to quantify mRNA levels.
  • Xenograft mouse models to assess in vivo tumor growth.
  • Bioinformatic analysis to identify regulatory factors.

Main Results:

  • miR-134 overexpression suppressed proliferation, migration, and invasion, while inducing apoptosis in OS cells.
  • miR-134 directly targets VEGFA and MYCN mRNA, reducing their translation.
  • IRF1 was identified as a transcriptional activator of miR-134.
  • Overexpression of miR-134 inhibited tumor growth in vivo.

Conclusions:

  • miR-134 acts as a tumor suppressor in osteosarcoma.
  • IRF1 transcriptionally upregulates miR-134, inhibiting OS progression by targeting VEGFA and MYCN.
  • miR-134 and IRF1 represent potential therapeutic targets for osteosarcoma treatment.
Keywords:
IRF1MYCNVEGFAmiR-134osteosarcomatumorigenesis

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.1K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K